Document is current
Any future updates will be listed below
-
Authors
Bellosillo, Beatriz
Doubek, Michael
Tomuleasa, Ciprian
Griesshammer, Martin
Marchetti, Monia
Sacha, Tomasz
Gisslinger, Heinz
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Accepted: 29 October 2024
First Online: 10 December 2024
Conflict of interest
: B. Bellosillo: Astra-Zeneca: consultancy, speaker bureau, research grant, Janssen: consultancy, speaker bureau, Merck-Serono: speaker bureau, Novartis: consultancy, speaker bureau, Roche: speaker bureau, research grant ThermoFisher: speaker bureau, research grant, Pfizer: speaker bureau. M. Doubek: AbbVie, AOP Orphan, AstraZeneca, Johnson and Johnson, GSK consultancy and speaker bureau. M. Griesshammer: Amgen, AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK. M. Marchetti: GILEAD: consultancy, NOVARTIS: consultancy, speaker bureau, MSD: speaker bureau. T. Sacha: AOP Orphan, Novartis, GSK consultancy and speaker bureau. H. Gisslinger: AOP Orphan, Novartis, BMS and GSK consultancy and speaker bureau. C. Tomuleasa declares that he has no competing interests.
